查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1556577

非侵入性糖尿病治疗市场报告：2030 年趋势、预测与竞争分析

Non-Invasive Diabetes Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

非侵入性糖尿病治疗的趋势与预测

预计2024年至2030年全球非侵入性糖尿病治疗市场将以5.6%的复合年增长率成长。该市场的主要驱动因素是糖尿病盛行率的上升以及糖尿病患者对自我药疗的日益偏好。全球非侵入性糖尿病治疗市场未来性，在医院、居家医疗和诊所市场都有机会。

无创糖尿病治疗按细分领域

该研究包括按类型、应用和地区分類的全球非侵入性糖尿病治疗预测。

非侵入性糖尿病治疗市场洞察

Lucintel 预测，吸入型胰岛素预计将在预测期内达到最高成长。

在市场上，居家医疗预计将在预测期内实现最高成长。

由于人口中糖尿病的高盛行率以及该地区主要企业的存在，预计北美在预测期内将出现最高的增长。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球非侵入性糖尿病治疗市场预计将以5.6%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 此市场的主要驱动因素是糖尿病盛行率的上升以及糖尿病患者对自我药疗的日益偏好。

Q3.市场的主要细分市场是：

A3. 非侵入性糖尿病治疗市场未来性广阔，在医院、居家医疗和诊所市场都有机会。

Q4.市场的主要企业是：

A4. 非侵入性糖尿病治疗的主要企业有：

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计吸入胰岛素在预测期内将经历最高成长。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 北美地区预计将在预测期内实现最高成长，因为该地区拥有大量糖尿病人口和主要企业。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球非侵入性糖尿病治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球非侵入性糖尿病治疗市场趋势（2018-2023）与预测（2024-2030）
  • 全球非侵入性糖尿病治疗市场（按类型）
    • 口服胰岛素
    • 颊含胰岛素
    • 眼药水 胰岛素
    • 吸入胰岛素
    • 鼻用胰岛素
    • 经皮的
    • 其他的
  • 全球非侵入性糖尿病治疗市场（按应用）
    • 医院
    • 居家医疗
    • 诊所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球非侵入性糖尿病治疗市场区域分布
  • 北美无创糖尿病治疗市场
  • 欧洲无创糖尿病治疗市场
  • 亚太非侵入性糖尿病治疗市场
  • 其他区域非侵入性糖尿病治疗市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球非侵入性糖尿病治疗市场按类型分類的成长机会
    • 全球非侵入性糖尿病治疗市场的应用成长机会
    • 全球非侵入性糖尿病治疗市场按地区成长机会
  • 全球非侵入性糖尿病治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球非侵入性糖尿病治疗市场的产能
    • 全球非侵入性糖尿病治疗市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories
简介目录

Non-Invasive Diabetes Therapy Trends and Forecast

The future of the global non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets. The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Non-Invasive Diabetes Therapy by Segment

The study includes a forecast for the global non-invasive diabetes therapy by type, application, and region.

Non-Invasive Diabetes Therapy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Oral Insulin
  • Buccal Insulin
  • Ocular Insulin
  • Inhaled Insulin
  • Nasal Insulin
  • Transdermal
  • Others

Non-Invasive Diabetes Therapy Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Home Care Settings
  • Clinics
  • Others

Non-Invasive Diabetes Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Non-Invasive Diabetes Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive diabetes therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive diabetes therapy companies profiled in this report include-

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Non-Invasive Diabetes Therapy Market Insights

Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Within this market, home care setting is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Features of the Global Non-Invasive Diabetes Therapy Market

Market Size Estimates: Non-invasive diabetes therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive diabetes therapy market size by type, application, and region in terms of value ($B).

Regional Analysis: Non-invasive diabetes therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the non-invasive diabetes therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive diabetes therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for non-invasive diabetes therapy market?

Answer: The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the non-invasive diabetes therapy market?

Answer: The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

Q3. What are the major segments for non-invasive diabetes therapy market?

Answer: The future of the non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets.

Q4. Who are the key non-invasive diabetes therapy market companies?

Answer: Some of the key non-invasive diabetes therapy companies are as follows:

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Q5. Which non-invasive diabetes therapy market segment will be the largest in future?

Answer: Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Q6. In non-invasive diabetes therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the non-invasive diabetes therapy market by type (oral insulin, buccal insulin, ocular insulin, inhaled insulin, nasal insulin, transdermal, and others), application (hospitals, home care settings, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Diabetes Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Non-Invasive Diabetes Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Non-Invasive Diabetes Therapy Market by Type
    • 3.3.1: Oral Insulin
    • 3.3.2: Buccal Insulin
    • 3.3.3: Ocular Insulin
    • 3.3.4: Inhaled Insulin
    • 3.3.5: Nasal Insulin
    • 3.3.6: Transdermal
    • 3.3.7: Others
  • 3.4: Global Non-Invasive Diabetes Therapy Market by Application
    • 3.4.1: Hospitals
    • 3.4.2: Home Care Settings
    • 3.4.3: Clinics
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Non-Invasive Diabetes Therapy Market by Region
  • 4.2: North American Non-Invasive Diabetes Therapy Market
    • 4.2.1: North American Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.2.2: North American Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.3: European Non-Invasive Diabetes Therapy Market
    • 4.3.1: European Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.3.2: European Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.4: APAC Non-Invasive Diabetes Therapy Market
    • 4.4.1: APAC Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.4.2: APAC Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.5: ROW Non-Invasive Diabetes Therapy Market
    • 4.5.1: ROW Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.5.2: ROW Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Type
    • 6.1.2: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Application
    • 6.1.3: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Region
  • 6.2: Emerging Trends in the Global Non-Invasive Diabetes Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Non-Invasive Diabetes Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Diabetes Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bio Tex
  • 7.2: Calisto Medical
  • 7.3: Dexcom
  • 7.4: Bayer
  • 7.5: ACON Laboratories